A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C

Gastroenterology

Volumn 141, Issue 3, 2011, Pages

  Habersetzer, Franois ^a,b   Honnet, Géraldine ^c   Bain, Christine ^c   Maynardmuet, Marianne ^d   Leroy, Vincent ^e   Zarski, Jeanpierre ^e   Feray, Cyrille ^f   Baumert, Thomas F ^a,b   Bronowicki, Jeanpierre ^g   Doffol, Michel ^a,b   Trépo, Christian ^d   Agathon, Delphine ^c   Toh, Myewling ^c   Baudin, Martine ^c   Bonnefoy, Jeanyves ^c   Limacher, Jeanmarc ^c   Inchauspé, Genevive ^c,h  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c TRANSGENE S A   (France)

^d UNIVERSITÉ DE LYON   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h Service Hépatogastroentérologie   (France)

Author keywords

Immunity; Liver Disease; Therapeutic Vaccine; Virology

Indexed keywords

NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 5B; RECOMBINANT VACCINE; TG 4040; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; MALE; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; VIRUS LOAD;

EID: 80051490030     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.06.009     Document Type: Article

References (30)

1. B. Rehermann Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 2009 1745 1754
2. Y. Fake-Ytter, H. Kale, and K.D. Mullen Surprisingly small effect of antiviral treatments in patients with hepatitis C Ann Intern Med 136 2002 288 292 (Pubitemid 34150758)
3. M.P. Manns, H. Wedemeyer, and M. Cornberg Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 2006 1350 1359 (Pubitemid 44277369)
4. C.M. Lange, C. Sarrazin, and S. Zeuzem Specifically targeted anti-viral therapy for hepatitis C: a new era in therapy Aliment Pharmacol Ther 32 2010 14 28
5. G.T. Strickland, S.S. El-Kamary, and P. Klernerman Hepatitis C vaccine: supply and demand Lancet Infect Dis 8 2008 379 386 (Pubitemid 351697805)
6. J. Torresi, D. Johnson, and H. Wedemeyer Progress in the development of preventive and therapeutic vaccines for hepatitis C virus J Hepatol 54 2011 1273 1285
7. G. Inchauspé, G. Bach, and P. Martin Vaccination against hepatitis B and C: towards therapeutic application Int Rev in Immunol 28 2009 7 19
8. A. Folgori, S. Capone, and L. Ruggeri A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees Nat Med 12 2006 190 197 (Pubitemid 43214745)
9. G.A. Elmowalid, M. Qiao, and S.H. Jeong Immunization with hepatitits C virus-like particles results in control of hepatitis C virus infection in chimpanzees Proc Natl Acad Sci U S A 104 2007 8427 8432 (Pubitemid 47175504)
10. A. Fournillier, E. Gerossier, and A. Evlachev A hepatitis C virus vaccine candidate based on a Modified Virus Ankara induces long lasting and protective T-cell based immune responses Vaccine 25 2007 7339 7353 (Pubitemid 47484019)
11. A. Reyes-Sandoval, J.T. Harty, and S.M. Todryk Viral vector vaccines make memory T cells against malaria Immunology 121 2007 158 165 (Pubitemid 46663084)
12. G. Gasteiger, W. Kastenmuller, and R. Liapoci Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines J Virol 81 2007 11925 11936 (Pubitemid 47623824)
13. A. Mayr, H. Stickl, and H.K. Muller Der pockenimpfstamm MVA: marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwchten organismus [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism] Zentralbl Bakteriol Hyg 167 1978 375 390 (Pubitemid 9145179)
14. P.L. Earl, J.L. Americo, and L.S. Wyatt Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox Nature 428 2004 182 185 (Pubitemid 38374314)
15. B. Acres, and J.T. Bonnefoy Clinical development of MVA-based therapeutic vaccines Exp Rev Vaccines 7 2008 889 893
16. I. Drexler, C. Staib, and G. Sutter Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 6 2004 506 512 (Pubitemid 39551002)
17. G. Sutter, and B. Moss Non-replicating vaccinia vector efficiently expresses recombinant genes Proc Natl Acad Sci U S A 89 1992 10847 10851
18. T.J. Blanchard, A. Alcami, and P. Andrea Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as human vaccine J Gen Virol 79 1998 1159 1167 (Pubitemid 28203857)
19. B.D.A. Michelin, Z. Muller, and E. Stelzl Evaluation of the Abbott real-time HCV assay for quantitative detection of hepatitis C virus RNA J Clin Virol 38 2007 96 100 (Pubitemid 46074454)
20. H.M. Diepolder, J.T. Gerlach, and R. Zachoval Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection J Virol 71 1997 6011 6019 (Pubitemid 27304939)
21. M.R. Betts, M.C. Nason, and S.M. West HIV nonprogressors preferentially maintain highly functional HIV-specific CD8- T cells Blood 107 2006 4781 4789 (Pubitemid 43882629)
22. J.R. Almeida, D.A. Price, and L. Papagno Superior control of HIV-1 replication by CD8 T cells is reflected by their avidity, polyfunctionality, and clonal turnover J Exp Med 204 2007 2473 2485 (Pubitemid 47529331)
23. + memory T cells J Virol 82 2008 10017 10031
24. C.S. Klade, H. Wedemeyer, and T. Berg Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastroenterology 134 2008 1385 1395
25. Rolland M, Tavanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial Nat Med 201;17:366371
26. C. Ferrari Therapeutic vaccination for hepatitis C: can protective T-cell responses be restored after prolonged antigen exposure? Gastroenterology 134 2008 1601 1604 (Pubitemid 351615377)
27. N. Nakamoto, D.E. Kaplan, and J. Coleclough Functional restoration of HCV-specific CD8 T cells by PD1 blockade is defined by PD1 expression and compartmentalization Gastroenterology 134 2008 1927 1937
28. A. Aghemo, and M. Colombo Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era? Gastroenterology 138 2010 2546 2549
29. J. Delaloye, T. Roger, and G.-G. Steiner-Tardivel Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome Plos Pathogens 5 2009 e1000480
30. G. Gasteiger, W. Kastenmuller, and R. Ljapoci Cross-priming of cytotoxic T cells disctates antigen requisites for modified vaccinia virus Ankara vector vaccines J Virol 81 2007 11925 11936 (Pubitemid 47623824)